Article: AVANT's Rotavirus Vaccine Featured at Infectious Diseases Society Annual Meeting.

Strong Efficacy Data Supports Further Development of the Vaccine

NEEDHAM, Mass., Nov. 17 /PRNewswire/ -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that data from a Phase II efficacy trial of the Company's rotavirus vaccine were presented at the Infectious Diseases Society of America 36th Annual Meeting. The research findings, presented by lead investigator David Bernstein, M.D., Associate Director, Division of Infectious Diseases, at Cincinnati Children's Hospital Medical Center, showed that the vaccine provided a nearly ninety percent protection from rotavirus disease.

Speaking at the conference, Dr. Bernstein commented, "The ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!